Kiniksa Pharmaceuticals International, plc
$42.46
▲
1.43%
2026-04-21 07:45:00
www.kiniksa.com
NMS: KNSA
Explore Kiniksa Pharmaceuticals International, plc stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$3.25 B
Current Price
$42.46
52W High / Low
$50.03 / $19.62
Stock P/E
55.07
Book Value
$7.44
Dividend Yield
—
ROCE
12.37%
ROE
11.73%
Face Value
—
EPS
$0.75
Exp Qtr EPS
—
Sector
Healthcare
Industry
Drug Manufacturers - Specialty & Generic
Employees
366
Beta
0.06
Debt / Equity
1.67
Current Ratio
3.79
Quick Ratio
3.39
Forward P/E
29.03
Price / Sales
5.32
Enterprise Value
$3.2 B
EV / EBITDA
40.61
EV / Revenue
4.72
Rating
None
Target Price
$57.38
EPS Forecast (FY)
—
Pros
- Efficient use of capital employed.
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
Cons
- Valuation is rich on a P/E basis.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Eton Pharmaceuticals, Inc. | $25.28 | — | $683.2 M | — | -1.57% | -18.19% | $27.29 / $13.09 | $0.97 |
| 2. | United Therapeutics Corporation | $578.37 | 20.76 | $25.34 B | — | 20.73% | 19.71% | $607.89 / $272.12 | $162.6 |
| 3. | Phibro Animal Health Corporation | $56.51 | 24.91 | $2.29 B | 0.85% | 10.35% | 31.8% | $60.08 / $16.16 | $8.2 |
| 4. | Emergent BioSolutions Inc. | $8.35 | 8.47 | $445.43 M | — | 9.47% | 10.46% | $14.06 / $4.45 | $10.03 |
| 5. | InterCure Ltd. | $0.75 | — | $125.93 M | — | -8.41% | -16.68% | $605 / $225.3 | $7.59 |
| 6. | Supernus Pharmaceuticals, Inc. | $51.25 | — | $2.92 B | — | -3.31% | -3.68% | $59.68 / $29.16 | $18.48 |
| 7. | Canopy Growth Corporation | $1.2 | — | $709.79 M | — | -8.06% | -48.5% | $3.28 / $1.18 | $1.49 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | |
|---|---|---|---|---|---|
| Sales | 202.13 M | 180.85 M | 156.8 M | 137.78 M | 122.54 M |
| Operating Profit | 19.77 M | 24.02 M | 20.16 M | 13.27 M | -19.3 M |
| Net Profit | 14.2 M | 18.43 M | 17.83 M | 8.54 M | -8.89 M |
| EPS in Rs | 0.31 | 0.4 | 0.39 | 0.19 | -0.19 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 677.56 M | 423.24 M | 270.26 M | 220.18 M |
| Operating Profit | 77.22 M | -45.62 M | -25.2 M | 9.77 M |
| Net Profit | 59.01 M | -43.19 M | 14.08 M | 183.36 M |
| EPS in Rs | 1.29 | -0.94 | 0.31 | 3.99 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 763.63 M | 580.55 M | 526.32 M | 459.67 M |
| Total Liabilities | 196.03 M | 142.12 M | 87.48 M | 63.52 M |
| Equity | 567.61 M | 438.44 M | 438.84 M | 396.15 M |
| Current Assets | 527.18 M | 331.8 M | 276.3 M | 243.06 M |
| Current Liabilities | 139.18 M | 100.62 M | 63.67 M | 47.07 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | 137.99 M | 25.69 M | 13.3 M | 5.81 M |
| Investing CF | -188.99 M | 37.67 M | -29.56 M | -8.08 M |
| Financing CF | 33.02 M | 12.27 M | 1.5 M | 2.52 M |
| Free CF | 136.42 M | 25.41 M | 13.17 M | 5.7 M |
| Capex | -1.57 M | -0.28 M | -0.13 M | -0.1 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 56.6% | 22.74% | — | — |
| Earnings Growth % | -406.68% | -92.32% | — | — |
| Profit Margin % | -10.21% | 5.21% | 83.28% | — |
| Operating Margin % | -10.78% | -9.32% | 4.44% | — |
| Gross Margin % | 85.61% | 87.64% | 89.6% | — |
| EBITDA Margin % | -10.38% | -8.46% | 5.53% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.